1.
Chem Commun (Camb)
; 54(36): 4521-4524, 2018 May 01.
Article
in English
| MEDLINE
| ID: mdl-29629444
ABSTRACT
Cyclin-dependent kinases have emerged as important targets for cancer therapy. HSD992, containing a novel scaffold based on the tetrahydro-3H-pyrazolo[4,3-a]phenanthridine core, inhibits CDK2/3 but not other CDKs and also potently inhibits several cancer cell lines.